Europe
Despite some setbacks, the company anticipates its vaccine could be available for use in the United Kingdom within the next several weeks.
Novartis is acquiring Cambridge, Massachusetts-based Cadent Therapeutics for $210 million up front and a possible $560 million in milestone payments.
The company is significantly expanding its footprint with new facilities in the United States and in Europe.
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
Novartis’ Entresto is well on its way to receiving approval as a treatment for heart failure patients following overwhelming support from a U.S. Food and Drug Administration (FDA) advisory committee.
It’s been a busy day so far for biopharma news and updates. Read on for more.
A little more than one year after Gilead Sciences and Galapagos NV announced intentions to seek regulatory approval for Jyseleca (filgotinib) as a treatment for rheumatoid arthritis, the companies have pulled the plug on that goal.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for December 15, 2020.
Germany’s CureVac announced it has enrolled the first volunteer in the pivotal Phase IIb/III trial of its own mRNA vaccine candidate, CVnCoV against COVID-19.
The deal has been approved by both companies’ boards and is expected to close in the third quarter of 2021.
PRESS RELEASES